The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COSTEM 2019 | Can CAR-T cells replace ASCT in DLBCL?
Michael Bishop, MD, University of Chicago Medical Center, Chicago, IL, discusses the possibility of CAR-T cells in replacing autologous stem cell transplantation (ASCT) in diffuse large B-cell lymphoma (DLBCL). This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.
